JW Bioscience licenses pancreatic cancer technology

Home > Business > Industry

print dictionary print

JW Bioscience licenses pancreatic cancer technology

Hahm Eun-kyung, left, CEO of JW Bioscience, and Patrik Dahlen, CEO of Immunovia AB, pose for a photo after signing an agreement online to license the Korean company’s technology to detect pancreatic cancer. [JW BIOSCIENCE]

Hahm Eun-kyung, left, CEO of JW Bioscience, and Patrik Dahlen, CEO of Immunovia AB, pose for a photo after signing an agreement online to license the Korean company’s technology to detect pancreatic cancer. [JW BIOSCIENCE]

 
JW Bioscience signed an agreement with Swedish diagnostic products company Immunovia AB to license its technology for early detection of pancreatic cancer, the company said Tuesday.
 
JW Bioscience has developed technology to detect pancreatic cancer in its early stages using two biomarkers — CFB and CA19-9. JW Bioscience holds patents on the technology in Korea, the United States, China, Japan and 21 European countries.
 
Under the deal, Immunovia gets global commercial rights for the two biomarkers, though specific details about the contract and monetary terms have not been disclosed.
 
The licensing deal with Immunovia will help JW Bioscience “increase its presence in the global in vitro diagnostics market,” the company said.
 
JW Bioscience is developing a test kit that can detect pancreatic cancers using the two biomarkers. If commercialized, the test kit could be used in early diagnosis of the disease with a minimum amount of blood samples.
 
Pancreatic cancers cause about 1,000 deaths per a day. The five-year relative survival rates for pancreatic cancer — which refers to the percentage of all patients who are alive five years after diagnosis — is only 12 percent, the lowest among all types of cancers, according to JW Bioscience.
 
“The deal is meaningful in that JW’s patents have been recognized in the global market, as well as the technologies we own,” said Hahm Eun-kyung, CEO of JW Bioscience. “With the cooperation with Immunovia, we will be able to strengthen our technological competitiveness about the two biomarkers CFB and CA19-9.” 

BY SARAH CHEA [chea.sarah@joongang.co.kr]
Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
s
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)

What’s Popular Now